You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCilazapril
Accession NumberDB01340
TypeSmall Molecule
GroupsApproved
DescriptionCilazapril is an ACE inhibtor class drug used in the treatment of hypertension and heart failure. It belongs to the angiotensin-converting enzyme inhibitors (ACE inhibitors) class of drugs. It is a prodrug that is hydrolyzed after absorption to its main metabolite cilazaprilat. It is branded as Inhibace in Canada and other countries, Vascace and Dynorm in a number of European countries, among many other names. None of these varieties are available in the United States.
Structure
Thumb
Synonyms
Cilazapril
Cilazapril anhydrous
Cilazaprilum
External Identifiers
  • Ro 31-2848
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Cilazapriltablet2.5 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Cilazapriltablet5.0 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Cilazapriltablet5 mgoralSanis Health Inc2010-05-312014-08-01Canada
Cilazapriltablet1 mgoralSanis Health Inc2010-05-31Not applicableCanada
Cilazapriltablet1.0 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Cilazapriltablet2.5 mgoralSanis Health Inc2010-05-31Not applicableCanada
Co Cilazapriltablet2.5 mgoralCobalt Pharmaceuticals Company2007-02-06Not applicableCanada
Co Cilazapriltablet5.0 mgoralCobalt Pharmaceuticals Company2007-02-06Not applicableCanada
Co Cilazapriltablet1.0 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Dom-cilazapriltablet2.5 mgoralDominion PharmacalNot applicableNot applicableCanada
Dom-cilazapriltablet5.0 mgoralDominion PharmacalNot applicableNot applicableCanada
Dom-cilazapriltablet1.0 mgoralDominion PharmacalNot applicableNot applicableCanada
Inhibace Tab 1mgtablet1 mgoralHoffmann La Roche Limited1993-12-312010-07-21Canada
Inhibace Tab 2.5mgtablet2.5 mgoralHoffmann La Roche Limited1993-12-31Not applicableCanada
Inhibace Tab 5mgtablet5 mgoralHoffmann La Roche Limited1993-12-31Not applicableCanada
Mylan-cilazapriltablet5.0 mgoralMylan Pharmaceuticals Ulc2006-07-21Not applicableCanada
Mylan-cilazapriltablet1 mgoralMylan Pharmaceuticals Ulc2006-07-21Not applicableCanada
Mylan-cilazapriltablet2.5 mgoralMylan Pharmaceuticals Ulc2006-07-21Not applicableCanada
Ntp-cilazapriltablet1 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-cilazapriltablet2.5 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-cilazapriltablet5 mgoralTeva Canada LimitedNot applicableNot applicableCanada
PHL-cilazapriltablet2.5 mgoralPharmel Inc2008-10-30Not applicableCanada
PHL-cilazapriltablet5.0 mgoralPharmel Inc2008-10-30Not applicableCanada
PHL-cilazapriltablet1.0 mgoralPharmel Inc2008-10-30Not applicableCanada
PMS-cilazapriltablet5.0 mgoralPharmascience Inc2006-06-09Not applicableCanada
PMS-cilazapriltablet1.0 mgoralPharmascience Inc2006-06-09Not applicableCanada
PMS-cilazapriltablet2.5 mgoralPharmascience Inc2006-06-09Not applicableCanada
Teva-cilazapriltablet5 mgoralTeva Canada Limited2005-04-01Not applicableCanada
Teva-cilazapriltablet1 mgoralTeva Canada Limited2005-04-01Not applicableCanada
Teva-cilazapriltablet2.5 mgoralTeva Canada Limited2005-04-01Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-cilazapriltablet1 mgoralApotex Inc2007-02-01Not applicableCanada
Apo-cilazapriltablet2.5 mgoralApotex Inc2007-02-01Not applicableCanada
Apo-cilazapriltablet5 mgoralApotex Inc2007-02-01Not applicableCanada
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DynormRoche
InhibaceRoche
InhibestrilTeva
VascaceRoche
ZaprilMylan
ZoboxHemofarm
Brand mixtures
NameLabellerIngredients
Apo-cilazapril/hctzApotex Inc
Inhibace Plus - TabHoffmann La Roche Limited
Novo-cilazapril/hctzTeva Canada Limited
Salts
Name/CASStructureProperties
Cilazapril monohydrate
92077-78-6
Thumb
  • InChI Key: JQRZBPFGBRIWSN-YOTVLOEGSA-N
  • Monoisotopic Mass: 435.236935795
  • Average Mass: 435.521
DBSALT001097
Categories
UNII8Q9454114Q
CAS number88768-40-5
WeightAverage: 417.4986
Monoisotopic: 417.226371117
Chemical FormulaC22H31N3O5
InChI KeyInChIKey=HHHKFGXWKKUNCY-FHWLQOOXSA-N
InChI
InChI=1S/C22H31N3O5/c1-2-30-22(29)18(13-12-16-8-4-3-5-9-16)23-17-10-6-14-24-15-7-11-19(21(27)28)25(24)20(17)26/h3-5,8-9,17-19,23H,2,6-7,10-15H2,1H3,(H,27,28)/t17-,18-,19-/m0/s1
IUPAC Name
(1S,9S)-9-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}-10-oxo-octahydro-1H-pyridazino[1,2-a][1,2]diazepine-1-carboxylic acid
SMILES
CCOC(=O)[[email protected]](CCC1=CC=CC=C1)N[[email protected]]1CCCN2CCC[[email protected]](N2C1=O)C(O)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as alpha amino acid esters. These are ester derivatives of alpha amino acids.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentAlpha amino acid esters
Alternative Parents
Substituents
  • Alpha-amino acid ester
  • Phenylpropylamine
  • Aralkylamine
  • Fatty acid ester
  • Diazepane
  • 1,2-diazepane
  • Fatty acyl
  • Benzenoid
  • Pyridazine
  • Dicarboxylic acid or derivatives
  • 1,2-diazinane
  • Monocyclic benzene moiety
  • Carboxylic acid hydrazide
  • Carboxylic acid ester
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Secondary amine
  • Secondary aliphatic amine
  • Carboxylic acid
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationCilazapril is an ACE inhibtor class drug used in the treatment of hypertension and heart failure.
PharmacodynamicsCilazapril inhibits the production angiotensin II. By doing so, it decreases sodium and water reabsorption (via aldosterone) and it decreases vasoconstriction. The combined effect of this is a decrease in vascular resistance, and therefore, blood pressure. The absolute bioavailability of cilazaprilat after oral administration of cilazapril is 57% based on urinary recovery data. (The absolute bioavailability of cilazaprilat after oral administration of cilazaprilat is 19%.) Ingestion of food immediately before the administration of cilazapril reduces the average peak plasma concentration of cilazaprilat by 29%, delays the peak by one hour and reduces the bioavailability of cilazaprilat by 14%. These pharmacokinetic changes have little influence on plasma ACE inhibition.
Mechanism of actionCilazapril is a pyridazine ACE inhibitor. It competes with angiotensin I for binding at the angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II. As angiotensin II is a vasoconstrictor and a negative feedback mediator for renin activity, lower angiotensin II levels results in a decrease in blood pressure, an increase in renin activity, and stimulation of baroreceptor reflex mechanisms. Kininase II, an enzyme which degrades the vasodilator bradykinin, is identical to ACE and may also be inhibited.
Related Articles
AbsorptionMaximum plasma concentrations of cilazaprilat are reached within two hours after administration of cilazapril.
Volume of distributionNot Available
Protein bindingMaximum ACE inhibition is greater than 90% after 1 to 5 mg cilazapril. Maximum ACE inhibition is 70 to 80% after 0.5 mg cilazapril. Dose proportionality is observed following the administration of 1 to 5 mg cilazapril. Apparent non-proportionality is observed at 0.5 mg reflective of the binding to ACE. The higher doses of cilazapril are associated with longer duration of maximum ACE inhibition.
Metabolism
SubstrateEnzymesProduct
Cilazapril
Not Available
CilazaprilatDetails
Route of eliminationCilazaprilat is eliminated unchanged by the kidneys. The total urinary recovery of cilazaprilat after intravenous administration of 2.5 mg is 91%.
Half lifeHalf-lives for the periods 1 to 4 hours and 1 to 7 days after the intravenous administration of 2.5 mg cilazaprilat are 0.90 and 46.2 hours respectively.
Clearance

Total clearance is 12.3 L/h and renal clearance is 10.8 L/h. The total urinary recovery of cilazaprilat following the oral administration of 2.5 mg cilazapril is 52.6%.

ToxicityLimited data are available with regard to overdosage in humans. The most likely manifestations are hypotension, which may be severe, hyperkalaemia, hyponatraemia and renal impairment with metabolic acidosis. Treatment should be mainly symptomatic and supportive.
Affected organismsNot Available
Pathways
PathwayCategorySMPDB ID
Cilazapril Metabolism PathwayDrug metabolismSMP00592
Cilazapril Action PathwayDrug actionSMP00147
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9157
Blood Brain Barrier-0.9402
Caco-2 permeable-0.7698
P-glycoprotein substrateSubstrate0.8727
P-glycoprotein inhibitor IInhibitor0.7775
P-glycoprotein inhibitor IINon-inhibitor0.8788
Renal organic cation transporterNon-inhibitor0.8318
CYP450 2C9 substrateNon-substrate0.7876
CYP450 2D6 substrateNon-substrate0.8283
CYP450 3A4 substrateSubstrate0.5396
CYP450 1A2 substrateNon-inhibitor0.882
CYP450 2C9 inhibitorNon-inhibitor0.7804
CYP450 2D6 inhibitorNon-inhibitor0.7503
CYP450 2C19 inhibitorNon-inhibitor0.816
CYP450 3A4 inhibitorNon-inhibitor0.8201
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8376
Ames testNon AMES toxic0.6023
CarcinogenicityNon-carcinogens0.9028
BiodegradationNot ready biodegradable0.9942
Rat acute toxicity2.3700 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9311
hERG inhibition (predictor II)Inhibitor0.6303
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Tabletoral
Tabletoral2.5 mg
Tabletoral5 mg
Tabletoral1 mg
Tabletoral1.0 mg
Tabletoral5.0 mg
Prices
Unit descriptionCostUnit
Inhibace 5 mg Tablet0.94USD tablet
Inhibace 2.5 mg Tablet0.81USD tablet
Inhibace 1 mg Tablet0.7USD tablet
Apo-Cilazapril 5 mg Tablet0.52USD tablet
Co Cilazapril 5 mg Tablet0.52USD tablet
Mylan-Cilazapril 5 mg Tablet0.52USD tablet
Novo-Cilazapril 5 mg Tablet0.52USD tablet
Pms-Cilazapril 5 mg Tablet0.52USD tablet
Apo-Cilazapril 2.5 mg Tablet0.45USD tablet
Co Cilazapril 2.5 mg Tablet0.45USD tablet
Mylan-Cilazapril 2.5 mg Tablet0.45USD tablet
Novo-Cilazapril 2.5 mg Tablet0.45USD tablet
Pms-Cilazapril 2.5 mg Tablet0.45USD tablet
Apo-Cilazapril 1 mg Tablet0.39USD tablet
Mylan-Cilazapril 1 mg Tablet0.39USD tablet
Novo-Cilazapril 1 mg Tablet0.39USD tablet
Pms-Cilazapril 1 mg Tablet0.39USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US20060293517 No2004-03-082024-03-08Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point98 ºC with decomposition Not Available
water solubilityWater (25 ºC) 0.5 g/100 mL Not Available
logP0.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.06 mg/mLALOGPS
logP-0.2ALOGPS
logP-0.0079ChemAxon
logS-2.6ALOGPS
pKa (Strongest Acidic)3.41ChemAxon
pKa (Strongest Basic)5.35ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area99.18 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity110.56 m3·mol-1ChemAxon
Polarizability44.73 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Attwood, M. R.; Hassall, C. H.; Kr�Hn, A.; Lawton, G.; Redshaw, S. (1986). “The design and synthesis of the Angiotensin Converting Enzyme inhibitor Cilazapril and related bicyclic compounds”. Journal of the Chemical Society, Perkin Transactions 1: 1011. doi:10.1039/P19860001011

US20060293517
General References
  1. Fasanella d'Amore T, Bussien JP, Nussberger J, Waeber B, Turini GA, Brunner HR, Kler L, Francis RJ: Effects of single doses of the converting enzyme inhibitor cilazapril in normal volunteers. J Cardiovasc Pharmacol. 1987 Jan;9(1):26-31. [PubMed:2434790 ]
External Links
ATC CodesC09BA08C09AA08
AHFS Codes
  • 24:32.04
PDB EntriesNot Available
FDA labelDownload (114 KB)
MSDSDownload (81.5 KB)
Interactions
Drug Interactions
Drug
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Cilazapril.
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Cilazapril.
AcebutololAcebutolol may increase the hypotensive activities of Cilazapril.
AceclofenacThe risk or severity of adverse effects can be increased when Cilazapril is combined with Aceclofenac.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Cilazapril.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Cilazapril.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Cilazapril is combined with Acetylsalicylic acid.
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Cilazapril.
AdapaleneThe risk or severity of adverse effects can be increased when Cilazapril is combined with Adapalene.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Cilazapril.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Cilazapril.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Cilazapril.
AlfuzosinAlfuzosin may increase the hypotensive activities of Cilazapril.
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Cilazapril.
AliskirenCilazapril may increase the hypotensive activities of Aliskiren.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Cilazapril.
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Cilazapril.
AlogliptinThe risk or severity of adverse effects can be increased when Alogliptin is combined with Cilazapril.
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Cilazapril.
AlprenololAlprenolol may increase the hypotensive activities of Cilazapril.
AmbrisentanCilazapril may increase the hypotensive activities of Ambrisentan.
AmifostineCilazapril may increase the hypotensive activities of Amifostine.
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Cilazapril.
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Cilazapril.
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Cilazapril.
Aminosalicylic AcidAminosalicylic Acid may decrease the antihypertensive activities of Cilazapril.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Cilazapril.
AmlodipineAmlodipine may increase the hypotensive activities of Cilazapril.
AmobarbitalAmobarbital may increase the hypotensive activities of Cilazapril.
Amyl NitriteThe risk or severity of adverse effects can be increased when Cilazapril is combined with Amyl Nitrite.
AntipyrineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Antipyrine.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Cilazapril.
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Cilazapril.
ApremilastThe risk or severity of adverse effects can be increased when Cilazapril is combined with Apremilast.
AprotininAprotinin may decrease the antihypertensive activities of Cilazapril.
ArdeparinArdeparin may increase the hyperkalemic activities of Cilazapril.
AripiprazoleAripiprazole may increase the hypotensive activities of Cilazapril.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Cilazapril.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Cilazapril.
AtenololAtenolol may increase the hypotensive activities of Cilazapril.
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Cilazapril.
AtorvastatinThe risk or severity of adverse effects can be increased when Atorvastatin is combined with Cilazapril.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Cilazapril.
AzapropazoneThe risk or severity of adverse effects can be increased when Cilazapril is combined with Azapropazone.
AzathioprineCilazapril may increase the myelosuppressive activities of Azathioprine.
AzelastineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Azelastine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Azilsartan medoxomil.
BalsalazideThe risk or severity of adverse effects can be increased when Cilazapril is combined with Balsalazide.
BarbitalBarbital may increase the hypotensive activities of Cilazapril.
BemiparinBemiparin may increase the hyperkalemic activities of Cilazapril.
BenazeprilBenazepril may increase the hypotensive activities of Cilazapril.
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Cilazapril.
BenmoxinBenmoxin may increase the hypotensive activities of Cilazapril.
BenoxaprofenThe risk or severity of adverse effects can be increased when Cilazapril is combined with Benoxaprofen.
BepridilBepridil may increase the hypotensive activities of Cilazapril.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Cilazapril.
BetaxololBetaxolol may increase the hypotensive activities of Cilazapril.
BethanidineBethanidine may increase the hypotensive activities of Cilazapril.
BimatoprostBimatoprost may increase the hypotensive activities of Cilazapril.
BisoprololBisoprolol may increase the hypotensive activities of Cilazapril.
BoceprevirThe serum concentration of Cilazapril can be decreased when it is combined with Boceprevir.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Cilazapril.
BosentanBosentan may increase the hypotensive activities of Cilazapril.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Cilazapril.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Cilazapril.
BretyliumBretylium may increase the hypotensive activities of Cilazapril.
BrimonidineCilazapril may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Cilazapril.
BromfenacThe risk or severity of adverse effects can be increased when Cilazapril is combined with Bromfenac.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Cilazapril.
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Cilazapril.
BupranololCilazapril may increase the hypotensive activities of Bupranolol.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Cilazapril.
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Cilazapril.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Cilazapril.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Cilazapril.
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Cilazapril.
CanagliflozinThe risk or severity of adverse effects can be increased when Cilazapril is combined with Canagliflozin.
CandesartanCandesartan may increase the hypotensive activities of Cilazapril.
CandoxatrilCandoxatril may increase the hypotensive activities of Cilazapril.
CaptoprilCaptopril may increase the hypotensive activities of Cilazapril.
CarbamazepineThe metabolism of Cilazapril can be increased when combined with Carbamazepine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Cilazapril.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Cilazapril.
CaroxazoneCaroxazone may increase the hypotensive activities of Cilazapril.
CarprofenThe risk or severity of adverse effects can be increased when Cilazapril is combined with Carprofen.
CarteololCarteolol may increase the hypotensive activities of Cilazapril.
CarvedilolCarvedilol may increase the hypotensive activities of Cilazapril.
CastanospermineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Castanospermine.
CelecoxibThe risk or severity of adverse effects can be increased when Cilazapril is combined with Celecoxib.
CeliprololCilazapril may increase the hypotensive activities of Celiprolol.
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Cilazapril.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Cilazapril.
CertoparinCertoparin may increase the hyperkalemic activities of Cilazapril.
ChloroquineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Chloroquine.
ChlorothiazideChlorothiazide may increase the hypotensive activities of Cilazapril.
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Cilazapril.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Cilazapril.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Cilazapril.
CiprofloxacinCilazapril may increase the arrhythmogenic activities of Ciprofloxacin.
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Cilazapril.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Cilazapril.
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Cilazapril.
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Cilazapril.
ClevidipineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Clevidipine.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Cilazapril.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Cilazapril.
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Cilazapril.
ClonidineClonidine may increase the hypotensive activities of Cilazapril.
ClonixinThe risk or severity of adverse effects can be increased when Cilazapril is combined with Clonixin.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Cilazapril.
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Cilazapril.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Cilazapril.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Cilazapril.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Cilazapril.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Cilazapril.
CryptenamineCryptenamine may increase the hypotensive activities of Cilazapril.
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Cilazapril.
CyclophosphamideThe risk or severity of adverse effects can be increased when Cilazapril is combined with Cyclophosphamide.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Cilazapril.
CyclothiazideCyclothiazide may increase the hypotensive activities of Cilazapril.
D-LimoneneThe risk or severity of adverse effects can be increased when Cilazapril is combined with D-Limonene.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Cilazapril.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Cilazapril.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Cilazapril.
DalteparinDalteparin may increase the hyperkalemic activities of Cilazapril.
DapagliflozinThe risk or severity of adverse effects can be increased when Cilazapril is combined with Dapagliflozin.
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Cilazapril.
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Cilazapril.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Cilazapril.
DebrisoquinCilazapril may increase the hypotensive activities of Debrisoquin.
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Cilazapril.
DeserpidineCilazapril may increase the hypotensive activities of Deserpidine.
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Cilazapril.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Cilazapril.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Cilazapril.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Cilazapril.
DiazoxideDiazoxide may increase the hypotensive activities of Cilazapril.
DiclofenacThe risk or severity of adverse effects can be increased when Cilazapril is combined with Diclofenac.
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Cilazapril.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Cilazapril.
DiflunisalThe risk or severity of adverse effects can be increased when Cilazapril is combined with Diflunisal.
DiflunisalDiflunisal may decrease the antihypertensive activities of Cilazapril.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Cilazapril.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Cilazapril.
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Cilazapril.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Cilazapril.
DiltiazemDiltiazem may increase the hypotensive activities of Cilazapril.
DinutuximabThe risk or severity of adverse effects can be increased when Cilazapril is combined with Dinutuximab.
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Cilazapril.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Cilazapril.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Cilazapril.
DorzolamideDorzolamide may increase the hypotensive activities of Cilazapril.
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Cilazapril.
DoxazosinDoxazosin may increase the hypotensive activities of Cilazapril.
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Cilazapril.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Cilazapril.
DrospirenoneCilazapril may increase the hyperkalemic activities of Drospirenone.
DroxicamThe risk or severity of adverse effects can be increased when Cilazapril is combined with Droxicam.
DuloxetineCilazapril may increase the orthostatic hypotensive activities of Duloxetine.
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Cilazapril.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Cilazapril.
EfonidipineCilazapril may increase the hypotensive activities of Efonidipine.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Cilazapril.
EmpagliflozinThe risk or severity of adverse effects can be increased when Cilazapril is combined with Empagliflozin.
EnalaprilEnalapril may increase the hypotensive activities of Cilazapril.
EnalaprilatCilazapril may increase the hypotensive activities of Enalaprilat.
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Cilazapril.
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Cilazapril.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Cilazapril.
EpirizoleThe risk or severity of adverse effects can be increased when Cilazapril is combined with Epirizole.
EplerenoneEplerenone may increase the hyperkalemic activities of Cilazapril.
EplerenoneThe risk or severity of adverse effects can be increased when Cilazapril is combined with Eplerenone.
EpoprostenolEpoprostenol may increase the hypotensive activities of Cilazapril.
EprosartanEprosartan may increase the hypotensive activities of Cilazapril.
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Cilazapril.
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Cilazapril.
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Cilazapril.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Cilazapril.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Cilazapril.
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Cilazapril.
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Cilazapril.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Cilazapril.
EstriolThe serum concentration of Estriol can be increased when it is combined with Cilazapril.
EstroneThe serum concentration of Estrone can be increased when it is combined with Cilazapril.
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Cilazapril.
EtanerceptThe risk or severity of adverse effects can be increased when Cilazapril is combined with Etanercept.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Cilazapril.
EtodolacThe risk or severity of adverse effects can be increased when Cilazapril is combined with Etodolac.
EtofenamateThe risk or severity of adverse effects can be increased when Cilazapril is combined with Etofenamate.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Cilazapril.
EtoricoxibThe risk or severity of adverse effects can be increased when Cilazapril is combined with Etoricoxib.
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Cilazapril.
Evening primrose oilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Evening primrose oil.
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Cilazapril.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Cilazapril.
exisulindThe risk or severity of adverse effects can be increased when Cilazapril is combined with exisulind.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Cilazapril.
FelodipineFelodipine may increase the hypotensive activities of Cilazapril.
FenbufenThe risk or severity of adverse effects can be increased when Cilazapril is combined with Fenbufen.
FenoldopamFenoldopam may increase the hypotensive activities of Cilazapril.
FenoprofenThe risk or severity of adverse effects can be increased when Cilazapril is combined with Fenoprofen.
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Cilazapril.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Cilazapril.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Cilazapril.
FloctafenineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Floctafenine.
FlunixinThe risk or severity of adverse effects can be increased when Cilazapril is combined with Flunixin.
FlurbiprofenThe risk or severity of adverse effects can be increased when Cilazapril is combined with Flurbiprofen.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Cilazapril.
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Cilazapril.
FosinoprilFosinopril may increase the hypotensive activities of Cilazapril.
FurazolidoneFurazolidone may increase the hypotensive activities of Cilazapril.
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Cilazapril.
GarlicThe serum concentration of Cilazapril can be decreased when it is combined with Garlic.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Cilazapril.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Cilazapril.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Cilazapril.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Cilazapril.
GuanabenzGuanabenz may increase the hypotensive activities of Cilazapril.
GuanadrelGuanadrel may increase the hypotensive activities of Cilazapril.
GuanethidineGuanethidine may increase the hypotensive activities of Cilazapril.
GuanfacineGuanfacine may increase the hypotensive activities of Cilazapril.
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Cilazapril.
HeparinHeparin may increase the hyperkalemic activities of Cilazapril.
HexamethoniumCilazapril may increase the hypotensive activities of Hexamethonium.
HexobarbitalHexobarbital may increase the hypotensive activities of Cilazapril.
HMPL-004The risk or severity of adverse effects can be increased when Cilazapril is combined with HMPL-004.
HydracarbazineHydracarbazine may increase the hypotensive activities of Cilazapril.
HydralazineHydralazine may increase the hypotensive activities of Cilazapril.
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Cilazapril.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Cilazapril.
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Cilazapril.
IbuprofenThe risk or severity of adverse effects can be increased when Cilazapril is combined with Ibuprofen.
IbuproxamThe risk or severity of adverse effects can be increased when Cilazapril is combined with Ibuproxam.
IcatibantIcatibant may decrease the antihypertensive activities of Cilazapril.
IcatibantThe risk or severity of adverse effects can be increased when Cilazapril is combined with Icatibant.
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Cilazapril.
IloprostIloprost may increase the hypotensive activities of Cilazapril.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Cilazapril.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Cilazapril.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Cilazapril.
IndapamideIndapamide may increase the hypotensive activities of Cilazapril.
IndenololCilazapril may increase the hypotensive activities of Indenolol.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Cilazapril.
IndomethacinThe risk or severity of adverse effects can be increased when Cilazapril is combined with Indomethacin.
IndoprofenThe risk or severity of adverse effects can be increased when Cilazapril is combined with Indoprofen.
IndoraminCilazapril may increase the hypotensive activities of Indoramin.
IproclozideIproclozide may increase the hypotensive activities of Cilazapril.
IproniazidIproniazid may increase the hypotensive activities of Cilazapril.
IrbesartanIrbesartan may increase the hypotensive activities of Cilazapril.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Cilazapril.
IronThe risk or severity of adverse effects can be increased when Cilazapril is combined with Iron.
Iron DextranThe risk or severity of adverse effects can be increased when Cilazapril is combined with Iron Dextran.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Cilazapril.
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Cilazapril.
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Cilazapril.
IsoxicamThe risk or severity of adverse effects can be increased when Cilazapril is combined with Isoxicam.
IsoxsuprineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Isoxsuprine.
IsradipineIsradipine may increase the hypotensive activities of Cilazapril.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Cilazapril.
KebuzoneThe risk or severity of adverse effects can be increased when Cilazapril is combined with Kebuzone.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Cilazapril.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Cilazapril.
KetoprofenThe risk or severity of adverse effects can be increased when Cilazapril is combined with Ketoprofen.
KetorolacThe risk or severity of adverse effects can be increased when Cilazapril is combined with Ketorolac.
LabetalolLabetalol may increase the hypotensive activities of Cilazapril.
LacidipineCilazapril may increase the hypotensive activities of Lacidipine.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Cilazapril.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Cilazapril.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Cilazapril.
Lanthanum carbonateThe serum concentration of Cilazapril can be decreased when it is combined with Lanthanum carbonate.
LatanoprostLatanoprost may increase the hypotensive activities of Cilazapril.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Cilazapril.
LeflunomideThe risk or severity of adverse effects can be increased when Cilazapril is combined with Leflunomide.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Cilazapril.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Cilazapril.
LercanidipineLercanidipine may increase the hypotensive activities of Cilazapril.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Cilazapril.
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Cilazapril.
LevodopaCilazapril may increase the orthostatic hypotensive activities of Levodopa.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Cilazapril.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Cilazapril.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Cilazapril.
LinagliptinThe risk or severity of adverse effects can be increased when Linagliptin is combined with Cilazapril.
LisinoprilLisinopril may increase the hypotensive activities of Cilazapril.
LithiumThe serum concentration of Lithium can be increased when it is combined with Cilazapril.
LofexidineCilazapril may increase the hypotensive activities of Lofexidine.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Cilazapril.
LornoxicamThe risk or severity of adverse effects can be increased when Cilazapril is combined with Lornoxicam.
LosartanLosartan may increase the hypotensive activities of Cilazapril.
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Cilazapril.
LoxoprofenThe risk or severity of adverse effects can be increased when Cilazapril is combined with Loxoprofen.
LumiracoxibThe risk or severity of adverse effects can be increased when Cilazapril is combined with Lumiracoxib.
MacitentanCilazapril may increase the hypotensive activities of Macitentan.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Cilazapril is combined with Magnesium salicylate.
ManidipineCilazapril may increase the hypotensive activities of Manidipine.
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Cilazapril.
MasoprocolThe risk or severity of adverse effects can be increased when Cilazapril is combined with Masoprocol.
MebanazineMebanazine may increase the hypotensive activities of Cilazapril.
MecamylamineMecamylamine may increase the hypotensive activities of Cilazapril.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Cilazapril is combined with Meclofenamic acid.
Mefenamic acidThe risk or severity of adverse effects can be increased when Cilazapril is combined with Mefenamic acid.
MeloxicamThe risk or severity of adverse effects can be increased when Cilazapril is combined with Meloxicam.
MesalazineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Mesalazine.
MesalazineMesalazine may decrease the antihypertensive activities of Cilazapril.
MetamizoleThe risk or severity of adverse effects can be increased when Cilazapril is combined with Metamizole.
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Cilazapril.
MethohexitalMethohexital may increase the hypotensive activities of Cilazapril.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Cilazapril.
MethyclothiazideMethyclothiazide may increase the hypotensive activities of Cilazapril.
MethyclothiazideThe risk or severity of adverse effects can be increased when Cilazapril is combined with Methyclothiazide.
MethyldopaMethyldopa may increase the hypotensive activities of Cilazapril.
Methylene blueMethylene blue may increase the hypotensive activities of Cilazapril.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Cilazapril.
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Cilazapril.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Cilazapril.
MetipranololMetipranolol may increase the hypotensive activities of Cilazapril.
MetolazoneMetolazone may increase the hypotensive activities of Cilazapril.
MetoprololMetoprolol may increase the hypotensive activities of Cilazapril.
MibefradilCilazapril may increase the hypotensive activities of Mibefradil.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Cilazapril.
MinaprineMinaprine may increase the hypotensive activities of Cilazapril.
MinoxidilMinoxidil may increase the hypotensive activities of Cilazapril.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Cilazapril.
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Cilazapril.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Cilazapril.
MoclobemideMoclobemide may increase the hypotensive activities of Cilazapril.
MoexiprilMoexipril may increase the hypotensive activities of Cilazapril.
MolsidomineMolsidomine may increase the hypotensive activities of Cilazapril.
MorphineThe serum concentration of Morphine can be increased when it is combined with Cilazapril.
MoxonidineCilazapril may increase the hypotensive activities of Moxonidine.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Mycophenolate mofetil.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Cilazapril is combined with Mycophenolic acid.
NabumetoneThe risk or severity of adverse effects can be increased when Cilazapril is combined with Nabumetone.
NadololNadolol may increase the hypotensive activities of Cilazapril.
NadroparinNadroparin may increase the hyperkalemic activities of Cilazapril.
NaftifineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Naftifine.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Cilazapril.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Cilazapril.
NaproxenThe risk or severity of adverse effects can be increased when Cilazapril is combined with Naproxen.
NCX 4016The risk or severity of adverse effects can be increased when Cilazapril is combined with NCX 4016.
NebivololCilazapril may increase the hypotensive activities of Nebivolol.
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Cilazapril.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Cilazapril.
NepafenacThe risk or severity of adverse effects can be increased when Cilazapril is combined with Nepafenac.
NesiritideThe risk or severity of adverse effects can be increased when Cilazapril is combined with Nesiritide.
NialamideNialamide may increase the hypotensive activities of Cilazapril.
NicardipineNicardipine may increase the hypotensive activities of Cilazapril.
NicorandilNicorandil may increase the hypotensive activities of Cilazapril.
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Cilazapril.
Niflumic AcidThe risk or severity of adverse effects can be increased when Cilazapril is combined with Niflumic Acid.
NiguldipineCilazapril may increase the hypotensive activities of Niguldipine.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Cilazapril.
NilvadipineCilazapril may increase the hypotensive activities of Nilvadipine.
NimesulideThe risk or severity of adverse effects can be increased when Cilazapril is combined with Nimesulide.
NimodipineNimodipine may increase the hypotensive activities of Cilazapril.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Cilazapril.
NisoldipineNisoldipine may increase the hypotensive activities of Cilazapril.
NitrendipineNitrendipine may increase the hypotensive activities of Cilazapril.
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Cilazapril.
NitroprussideNitroprusside may increase the hypotensive activities of Cilazapril.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Cilazapril.
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Cilazapril.
ObinutuzumabCilazapril may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Cilazapril.
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Cilazapril.
OlmesartanOlmesartan may increase the hypotensive activities of Cilazapril.
OlopatadineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Olopatadine.
OlsalazineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Olsalazine.
OmapatrilatOmapatrilat may increase the hypotensive activities of Cilazapril.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Cilazapril.
OrgoteinThe risk or severity of adverse effects can be increased when Cilazapril is combined with Orgotein.
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Cilazapril.
OxaprozinThe risk or severity of adverse effects can be increased when Cilazapril is combined with Oxaprozin.
OxprenololCilazapril may increase the hypotensive activities of Oxprenolol.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Cilazapril is combined with Oxyphenbutazone.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Cilazapril.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Cilazapril.
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Cilazapril.
ParecoxibThe risk or severity of adverse effects can be increased when Cilazapril is combined with Parecoxib.
PargylineCilazapril may increase the hypotensive activities of Pargyline.
ParnaparinParnaparin may increase the hyperkalemic activities of Cilazapril.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Cilazapril.
PenbutololCilazapril may increase the hypotensive activities of Penbutolol.
PentobarbitalPentobarbital may increase the hypotensive activities of Cilazapril.
PentoliniumPentolinium may increase the hypotensive activities of Cilazapril.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Cilazapril.
PerindoprilPerindopril may increase the hypotensive activities of Cilazapril.
PethidineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Pethidine.
PhenelzinePhenelzine may increase the hypotensive activities of Cilazapril.
PheniprazinePheniprazine may increase the hypotensive activities of Cilazapril.
PhenobarbitalPhenobarbital may increase the hypotensive activities of Cilazapril.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Cilazapril.
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Cilazapril.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Cilazapril.
PhentolaminePhentolamine may increase the hypotensive activities of Cilazapril.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Cilazapril is combined with Phenylbutazone.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Cilazapril.
PimecrolimusThe risk or severity of adverse effects can be increased when Cilazapril is combined with Pimecrolimus.
PimozideThe serum concentration of Pimozide can be increased when it is combined with Cilazapril.
PinacidilCilazapril may increase the hypotensive activities of Pinacidil.
PindololPindolol may increase the hypotensive activities of Cilazapril.
PiretanidePiretanide may increase the hypotensive activities of Cilazapril.
PirfenidoneThe risk or severity of adverse effects can be increased when Cilazapril is combined with Pirfenidone.
PirlindolePirlindole may increase the hypotensive activities of Cilazapril.
PiroxicamThe risk or severity of adverse effects can be increased when Cilazapril is combined with Piroxicam.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Cilazapril.
PivhydrazinePivhydrazine may increase the hypotensive activities of Cilazapril.
PolythiazidePolythiazide may increase the hypotensive activities of Cilazapril.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Cilazapril.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Cilazapril.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Cilazapril.
PrazosinPrazosin may increase the hypotensive activities of Cilazapril.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Cilazapril.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Cilazapril.
PregabalinThe risk or severity of adverse effects can be increased when Cilazapril is combined with Pregabalin.
PrimidonePrimidone may increase the hypotensive activities of Cilazapril.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Cilazapril.
PropacetamolThe risk or severity of adverse effects can be increased when Cilazapril is combined with Propacetamol.
PropranololPropranolol may increase the hypotensive activities of Cilazapril.
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Cilazapril.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Cilazapril.
PTC299The risk or severity of adverse effects can be increased when Cilazapril is combined with PTC299.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Cilazapril.
QuinaprilQuinapril may increase the hypotensive activities of Cilazapril.
QuinethazoneQuinethazone may increase the hypotensive activities of Cilazapril.
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Cilazapril.
QuinineQuinine may increase the hypotensive activities of Cilazapril.
QuinineThe serum concentration of Quinine can be increased when it is combined with Cilazapril.
RamiprilRamipril may increase the hypotensive activities of Cilazapril.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Cilazapril.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Cilazapril.
RasagilineRasagiline may increase the hypotensive activities of Cilazapril.
RemikirenRemikiren may increase the hypotensive activities of Cilazapril.
RescinnamineCilazapril may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Cilazapril.
ResveratrolThe risk or severity of adverse effects can be increased when Cilazapril is combined with Resveratrol.
ReviparinReviparin may increase the hyperkalemic activities of Cilazapril.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Cilazapril.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Cilazapril.
RiociguatCilazapril may increase the hypotensive activities of Riociguat.
RisperidoneCilazapril may increase the hypotensive activities of Risperidone.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Cilazapril.
RituximabCilazapril may increase the hypotensive activities of Rituximab.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Cilazapril.
RofecoxibThe risk or severity of adverse effects can be increased when Cilazapril is combined with Rofecoxib.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Cilazapril.
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Cilazapril.
SacubitrilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Sacubitril.
SafrazineSafrazine may increase the hypotensive activities of Cilazapril.
SalicylamideThe risk or severity of adverse effects can be increased when Cilazapril is combined with Salicylamide.
Salicylic acidThe risk or severity of adverse effects can be increased when Cilazapril is combined with Salicylic acid.
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Cilazapril.
SalsalateThe risk or severity of adverse effects can be increased when Cilazapril is combined with Salsalate.
SaprisartanCilazapril may increase the hypotensive activities of Saprisartan.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Cilazapril.
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Cilazapril.
SaxagliptinThe risk or severity of adverse effects can be increased when Saxagliptin is combined with Cilazapril.
SecobarbitalSecobarbital may increase the hypotensive activities of Cilazapril.
SelegilineSelegiline may increase the hypotensive activities of Cilazapril.
SelexipagCilazapril may increase the hypotensive activities of Selexipag.
SeratrodastThe risk or severity of adverse effects can be increased when Cilazapril is combined with Seratrodast.
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Cilazapril.
SildenafilSildenafil may increase the antihypertensive activities of Cilazapril.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Cilazapril.
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Cilazapril.
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Cilazapril.
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Cilazapril.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Cilazapril.
SitagliptinThe risk or severity of adverse effects can be increased when Sitagliptin is combined with Cilazapril.
SitaxentanCilazapril may increase the hypotensive activities of Sitaxentan.
Sodium aurothiomalateThe risk or severity of adverse effects can be increased when Cilazapril is combined with Sodium aurothiomalate.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Cilazapril.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Cilazapril.
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Cilazapril.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Cilazapril.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Cilazapril.
SpiraprilCilazapril may increase the hypotensive activities of Spirapril.
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Cilazapril.
SRT501The risk or severity of adverse effects can be increased when Cilazapril is combined with SRT501.
St. John's WortThe metabolism of Cilazapril can be increased when combined with St. John's Wort.
SulfasalazineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Sulfasalazine.
SulindacThe risk or severity of adverse effects can be increased when Cilazapril is combined with Sulindac.
SuprofenThe risk or severity of adverse effects can be increased when Cilazapril is combined with Suprofen.
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Cilazapril.
TadalafilTadalafil may increase the antihypertensive activities of Cilazapril.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Cilazapril.
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Cilazapril.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Cilazapril.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Cilazapril.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Cilazapril.
TelmisartanTelmisartan may increase the hypotensive activities of Cilazapril.
TemocaprilCilazapril may increase the hypotensive activities of Temocapril.
TemsirolimusThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Cilazapril.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Cilazapril.
TenoxicamThe risk or severity of adverse effects can be increased when Cilazapril is combined with Tenoxicam.
TepoxalinThe risk or severity of adverse effects can be increased when Cilazapril is combined with Tepoxalin.
TerazosinThe risk or severity of adverse effects can be increased when Terazosin is combined with Cilazapril.
TeriflunomideThe risk or severity of adverse effects can be increased when Cilazapril is combined with Teriflunomide.
TerlipressinCilazapril may increase the hypotensive activities of Terlipressin.
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Cilazapril.
ThiamylalThiamylal may increase the hypotensive activities of Cilazapril.
ThiopentalThiopental may increase the hypotensive activities of Cilazapril.
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Cilazapril.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Cilazapril is combined with Tiaprofenic acid.
TiboloneCilazapril may increase the hypotensive activities of Tibolone.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Cilazapril.
TicrynafenCilazapril may increase the hypotensive activities of Ticrynafen.
TimololTimolol may increase the hypotensive activities of Cilazapril.
TinzaparinTinzaparin may increase the hyperkalemic activities of Cilazapril.
TipranavirThe serum concentration of Cilazapril can be decreased when it is combined with Tipranavir.
TizanidineTizanidine may increase the hypotensive activities of Cilazapril.
TizanidineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Tizanidine.
TolazolineTolazoline may increase the hypotensive activities of Cilazapril.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Cilazapril is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Cilazapril is combined with Tolmetin.
ToloxatoneToloxatone may increase the hypotensive activities of Cilazapril.
TolvaptanTolvaptan may increase the hyperkalemic activities of Cilazapril.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Cilazapril.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Cilazapril.
TorasemideTorasemide may increase the hypotensive activities of Cilazapril.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Cilazapril.
TrandolaprilTrandolapril may increase the hypotensive activities of Cilazapril.
TranilastThe risk or severity of adverse effects can be increased when Cilazapril is combined with Tranilast.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Cilazapril.
TranylcypromineTranylcypromine may increase the hypotensive activities of Cilazapril.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Cilazapril.
TravoprostTravoprost may increase the hypotensive activities of Cilazapril.
TreprostinilTreprostinil may increase the hypotensive activities of Cilazapril.
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Cilazapril.
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Cilazapril.
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Cilazapril.
TrimazosinCilazapril may increase the hypotensive activities of Trimazosin.
TrimethaphanTrimethaphan may increase the hypotensive activities of Cilazapril.
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Cilazapril.
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Cilazapril.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Trisalicylate-choline.
UdenafilUdenafil may increase the antihypertensive activities of Cilazapril.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Cilazapril.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Cilazapril.
UnoprostoneCilazapril may increase the hypotensive activities of Unoprostone.
ValdecoxibThe risk or severity of adverse effects can be increased when Cilazapril is combined with Valdecoxib.
ValsartanValsartan may increase the hypotensive activities of Cilazapril.
VardenafilVardenafil may increase the antihypertensive activities of Cilazapril.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Cilazapril.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Cilazapril.
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Cilazapril.
VildagliptinThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Cilazapril.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Cilazapril.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Cilazapril.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Cilazapril.
XylometazolineCilazapril may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Cilazapril.
ZaltoprofenThe risk or severity of adverse effects can be increased when Cilazapril is combined with Zaltoprofen.
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Cilazapril.
ZileutonThe risk or severity of adverse effects can be increased when Cilazapril is combined with Zileuton.
ZomepiracThe risk or severity of adverse effects can be increased when Cilazapril is combined with Zomepirac.
Food Interactions
  • Food decreases cilazapril absorption with no significant clinical impact.
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent vasodilator. Has also a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety.
Gene Name:
ACE
Uniprot ID:
P12821
Molecular Weight:
149713.675 Da
References
  1. Yoshiyama M, Takeuchi K, Omura T, Kim S, Yamagishi H, Toda I, Teragaki M, Akioka K, Iwao H, Yoshikawa J: Effects of candesartan and cilazapril on rats with myocardial infarction assessed by echocardiography. Hypertension. 1999 Apr;33(4):961-8. [PubMed:10205231 ]
  2. Kihara M, Mitsui MK, Mitsui Y, Okuda K, Nakasaka Y, Takahashi M, Schmelzer JD: Altered vasoreactivity to angiotensin II in experimental diabetic neuropathy: role of nitric oxide. Muscle Nerve. 1999 Jul;22(7):920-5. [PubMed:10398211 ]
  3. Mervaala E, Dehmel B, Gross V, Lippoldt A, Bohlender J, Milia AF, Ganten D, Luft FC: Angiotensin-converting enzyme inhibition and AT1 receptor blockade modify the pressure-natriuresis relationship by additive mechanisms in rats with human renin and angiotensinogen genes. J Am Soc Nephrol. 1999 Aug;10(8):1669-80. [PubMed:10446934 ]
  4. Rosendorff C, Patton J, Radford HM, Kalliatakis B: Alpha-adrenergic and angiotensin II pressor sensitivity in hypertensive patients treated with an angiotensin-converting enzyme inhibitor. J Cardiovasc Pharmacol. 1992;19 Suppl 6:S105-9. [PubMed:1382157 ]
  5. Hannedouche T, Ikeni A, Marques LP, Natov S, Dechaux M, Schmitt F, Lacour B, Grunfeld JP: Renal effects of angiotensin II in normotensive subjects on short-term cilazapril treatment. J Cardiovasc Pharmacol. 1992;19 Suppl 6:S25-7. [PubMed:1382161 ]
  6. Tylicki L, Rutkowski P, Renke M, Larczynski W, Aleksandrowicz E, Lysiak-Szydlowska W, Rutkowski B: Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. Am J Kidney Dis. 2008 Sep;52(3):486-93. doi: 10.1053/j.ajkd.2008.02.297. Epub 2008 Apr 18. [PubMed:18423812 ]
  7. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Takara K, Kakumoto M, Tanigawara Y, Funakoshi J, Sakaeda T, Okumura K: Interaction of digoxin with antihypertensive drugs via MDR1. Life Sci. 2002 Feb 15;70(13):1491-500. [PubMed:11895100 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name:
SLC15A1
Uniprot ID:
P46059
Molecular Weight:
78805.265 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Peptide:proton symporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
Gene Name:
SLC15A2
Uniprot ID:
Q16348
Molecular Weight:
81782.77 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951 ]
Comments
comments powered by Disqus
Drug created on June 30, 2007 12:09 / Updated on August 17, 2016 12:23